Premature Ejaculation ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Premature Ejaculation ' Pipeline Review, H2 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H2 2012', provides an overview of the Premature Ejaculation
therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest
updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic
development for Premature Ejaculation. 'Premature Ejaculation - Pipeline Review, H2 2012' is built using data and information
sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets
Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Premature Ejaculation.
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Premature Ejaculation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development
progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Premature
Ejaculation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Premature Ejaculation ' Pipeline Review, H2 2012 (From Slideshare) Page 1/7


Table of Content

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Premature Ejaculation Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Premature Ejaculation 8
Premature Ejaculation Therapeutics under Development by Companies 10
Premature Ejaculation Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Early Clinical Stage Products 15
Discovery and Pre-Clinical Stage Products 16
Premature Ejaculation Therapeutics ' Products under Development by Companies 17
Premature Ejaculation Therapeutics ' Products under Investigation by Universities/Institutes 18
Companies Involved in Premature Ejaculation Therapeutics Development 19
Johnson & Johnson 19
Shionogi & Co., Ltd. 20
GlaxoSmithKline plc 21
Dong-A Pharmaceutical Co., Ltd. 22
Futura Medical plc. 23
Plethora Solutions Holdings plc 24
Medisyn Technologies, Inc. 25
NeuroHealing Pharmaceuticals Inc. 26
Ampio Pharmaceuticals, Inc. 27
Premature Ejaculation ' Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
PSD502 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PSD502 - Drug Profile 35
R&D Progress 35



NH02D - Drug Profile 37
R&D Progress 37
DA-8031 - Drug Profile 38
R&D Progress 38
GSK557296 - Drug Profile 39
R&D Progress 39
Escitalopram - Drug Profile 41
R&D Progress 41
Priligy - Drug Profile 42
R&D Progress 42
PET500 - Drug Profile 44
R&D Progress 44
Clomipramine - Drug Profile 45
R&D Progress 45
Drug For Premature Ejaculation - Drug Profile 47
R&D Progress 47
Zertane - Drug Profile 48
R&D Progress 48
TUC204 - Drug Profile 50
R&D Progress 50
Premature Ejaculation Therapeutics ' Drug Profile Updates 51
Premature Ejaculation Therapeutics ' Discontinued Products 55
Premature Ejaculation Therapeutics - Dormant Products 56
Premature Ejaculation ' Product Development Milestones 57
Featured News & Press Releases 57
Jul 02, 2012: Ampio Pharma Contracts With Syngene To Manufacture Zertane-ED To Treat Both Premature Ejaculation And Erectile
Dysfunction 57
Jun 21, 2012: Ampio Pharma Reports Successful Type B Pre-IND Meeting With FDA For Zertane To Treat Premature Ejaculation 58



Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update 58
Apr 09, 2012: Ampio Submits Type B Pre IND Meeting Request To FDA For Zertane 59
Apr 02, 2012: Ampio Reaches Agreement With Therapeutic Goods Administration For Submission Plan For Zertane In Australia 59
Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502 60
Jan 31, 2012: European Commission Endorses Positive Opinion Of Priligy For On-demand Treatment Of Premature Ejaculation In All
EU Countries 61
Jan 17, 2012: Apricus Bio Announces Allowance Of Israeli Patent For Vitaros For Topical Treatment Of Premature Ejaculation 61
Jan 17, 2012: Ampio's Zertane Combinations To Receive Two New European Patents For Treatment Of Male Sexual Dysfunctions 62
Dec 19, 2011: Plethora Provides Update On PSD502 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables

Number of Products Under Development for Premature Ejaculation, H2 2012 8
Products under Development for Premature Ejaculation ' Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Johnson & Johnson, H2 2012 19
Shionogi & Co., Ltd., H2 2012 20
GlaxoSmithKline plc, H2 2012 21
Dong-A Pharmaceutical Co., Ltd., H2 2012 22
Futura Medical plc., H2 2012 23
Plethora Solutions Holdings plc, H2 2012 24
Medisyn Technologies, Inc., H2 2012 25
NeuroHealing Pharmaceuticals Inc., H2 2012 26
Ampio Pharmaceuticals, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Premature Ejaculation Therapeutics ' Drug Profile Updates 51
Premature Ejaculation Therapeutics ' Discontinued Products 55
Premature Ejaculation Therapeutics ' Dormant Products 56

List of Figures



Number of Products under Development for Premature Ejaculation, H2 2012 8
Products under Development for Premature Ejaculation ' Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Premature Ejaculation ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Premature Ejaculation ' Pipeline Review, H2 2012